Journal of the American Heart Association · 2026
Observed Versus Predicted Stroke Risk After Transient Ischemic Attack: A Post Hoc Analysis of a Randomized Clinical Trial.
СтатьяРандомизированное исследованиеМногоцентровое исследованиеПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Daghlas Iyas, Caunca Michelle R, Kim Anthony S
Аннотация
BACKGROUND: The ABCD2 score, used to triage patients with transient ischemic attack (TIA), was developed before contemporary use of dual antiplatelet therapy (DAPT) and therefore estimates pretreatment stroke risk. However, posttreatment stroke risk after DAPT may be more relevant for clinical triage. We aimed to quantify residual ischemic stroke risk following DAPT in patients with high-risk TIA.
METHODS: We conducted a post hoc analysis of high-risk patients with TIA enrolled in the POINT (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke) trial who were treated with DAPT. We calculated Kaplan-Meier estimates of ischemic stroke risk at 2, 7, and 90 days. Risk estimates were further stratified according to ABCD2 category (4-5 versus 6-7) and presence of infarct on index imaging despite symptom resolution. Observed risks were compared with ABCD2 predictions.
RESULTS: A total of 1052 POINT participants experienced a TIA and were treated with DAPT. Cumulative ischemic stroke risks were 1.3% (95% CI, 0.6-1.9) at 2 days, 2.0% (95% CI, 1.2-2.9) at 7 days, and 4.1% (95% CI, 2.8-5.3) at 90 days, all below ABCD2-predicted risks of 5.1, 7.4, and 11.9%, respectively. Incident ischemic stroke risk did not differ by ABCD2 category (P=0.80) but was higher in those with acute infarct on index imaging (P=0.02). In patients with infarct on imaging despite symptom resolution, 2-day ischemic stroke risk (3.4% [95% CI, 0.1-6.1]) approximated ABCD2 risk predictions, whereas those without evidence of infarct were at 6-fold lower 2-day risk (0.8% [95% CI, 0.0-1.4]).
CONCLUSIONS: High-risk patients with TIA treated with DAPT had substantially lower early stroke risk than predicted by ABCD2, particularly in the absence of acute infarct on neuroimaging.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT00991029.
METHODS: We conducted a post hoc analysis of high-risk patients with TIA enrolled in the POINT (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke) trial who were treated with DAPT. We calculated Kaplan-Meier estimates of ischemic stroke risk at 2, 7, and 90 days. Risk estimates were further stratified according to ABCD2 category (4-5 versus 6-7) and presence of infarct on index imaging despite symptom resolution. Observed risks were compared with ABCD2 predictions.
RESULTS: A total of 1052 POINT participants experienced a TIA and were treated with DAPT. Cumulative ischemic stroke risks were 1.3% (95% CI, 0.6-1.9) at 2 days, 2.0% (95% CI, 1.2-2.9) at 7 days, and 4.1% (95% CI, 2.8-5.3) at 90 days, all below ABCD2-predicted risks of 5.1, 7.4, and 11.9%, respectively. Incident ischemic stroke risk did not differ by ABCD2 category (P=0.80) but was higher in those with acute infarct on index imaging (P=0.02). In patients with infarct on imaging despite symptom resolution, 2-day ischemic stroke risk (3.4% [95% CI, 0.1-6.1]) approximated ABCD2 risk predictions, whereas those without evidence of infarct were at 6-fold lower 2-day risk (0.8% [95% CI, 0.0-1.4]).
CONCLUSIONS: High-risk patients with TIA treated with DAPT had substantially lower early stroke risk than predicted by ABCD2, particularly in the absence of acute infarct on neuroimaging.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT00991029.